To speed up the?development and?commercialization and maximize the clinical and commercial value of our?innovative products, we have been?identifying?strategic partners globally with high value-added potential to cooperate in?partnership, joint venture, or licensing agreement.

?

In the different development stages of our company and products, we enhance our access through collaboration with Leading international and domestic pharmaceutical companies, including Merck, Summit Therapeutics, Dawnrays Pharmaceutical, Sino Biopharm, Pfizer, AstraZeneca, Chipscreen Biosciences, Duoning Biotechnology. In 2015，we out-licensed our CTLA-4 antibody (AK107) to Merck for a total consideration?of up to US$200 million. According to Frost & Sullivan, we are the first China-based biotech company to out-license a fully internally-discovered monoclonal antibody to a leading?global pharmaceutical.?In December 2022, we out-licensed?our breakthrough bispecific antibody, ivonescimab (PD-1/VEGF, AK112), with up to?US$5 Billion?to Summit Therapeutics for development and commercialization in the U.S., Canada, Europe, and Japan.?Those agreements?provide an expedited and winning pathway for our innovative drugs’?global development by partnering with world-class teams.

?

To accelerate the commercialization of our marketed products, we have established a joint venture company, CTTQ-Akeso, with Chia Tai Tianqing (CTTQ), a principal subsidiary of Sino Biopharm. Collaboratively, we plan to develop and commercialize our PD-1 antibody drug 安尼可^? (penpulimab), taking advantage of CTTQ's broad distribution channels and resources to broaden its market access.?

?

With more?globally advanced?potential FIC/BIC?drug?candidates?into clinical development, including AK129(PD-1/LAG3), AK130(TIGIT/TGFβ), AK131(PD-1/CD73), AK132(Claudin18.2/CD47), AK117(CD47), we will continually?integrate superior global resources and accelerate the global development of innovative drugs.

?

?